CT-102

N/A

Report date: 2022/05/11 12:40:10
NME

Base Information

Drug NameCT-102
Drug Alias NameCT102CT-102
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionInsulin-like growth factor I receptor antagonists
TargetsInsulin-like growth factor I receptor
Therapy Area/IndicationsLiver NeoplasmsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesInstitute Of Radiation And Radiation Medicine, Chinese Academy Of Military Medical SciencesHangzhou Tianlong Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHangzhou Tianlong Pharmaceutical Co LtdInstitute Of Radiation And Radiation Medicine, Chinese Academy Of Military Medical SciencesYoucare Pharmaceutical Group Co Ltd
Inactive CompaniesN/A
Active IndicationsLiver NeoplasmsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A